SCHEMBL6806878

SCHEMBL6806878

Cc1csc(N(C)CCOc2ccccc2C=O)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.48
HPGD P15428 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PTGDR2 Q9Y5Y4 1/20 0.39
ADRB2 P07550 1/20 0.38
ADRB1 P08588 1/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
RECQL P46063 1/20 0.38
MAPT P10636 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
ADRA1A P35348 1/20 0.36
LMNA P02545 2/20 0.36
RAB9A P51151 2/20 0.36
USP2 O75604 1/20 0.36
SLC12A5 Q9H2X9 1/20 0.35
HTR1B P28222 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8717050 0.85 RAB9A (0.48) ALDH1A1HPGDHTTSMN1; SMN2MAPT
SCHEMBL8719505 0.80 ALDH1A1 (0.50) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL6803223 0.79 PPARG (0.45) ALDH1A1HPGDHTTSMN1; SMN2KDM4E
SCHEMBL8717052 0.77 PPARG (0.54) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL8716770 0.77 ALDH1A1 (0.43) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL8716296 0.77 DHODH (0.46) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL8716783 0.76 ALDH1A1 (0.59) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL4888000 0.74 ALDH1A1 (0.69) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL8719648 0.73 ALDH1A1 (0.48) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL4034502 0.73 ALDH1A1 (0.54) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6686475-B2 THIAZOLIDINEDIONE DERIVATIVES HAVING HYPOGLYCAEMIC AND HYPOLIPIDAEMIC ACTIVITIES BEECHAM GROUP P.L.C. (GB) 2004-02-03 US disclosed
US-20020049240-A1 NOVEL COMPOUNDS BEECHAM GROUP P.1.C. 2002-04-25 US disclosed
US-6288095-B1 ADMINISTERING 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE TO MAMMALS AS AN ANTIDIABETIC BEECHAM GROUP P.L.C. (GB) 2001-09-11 US disclosed
US-5756525-A USING A THIAZOLIDINEDIONE COMPOUND BEECHAM GROUP PLC (GB) 1998-05-26 US disclosed
EP-0842925-A1 Substituted thiazolidinedione derivatives BEECHAM GROUP PLC (GB) 1998-05-20 EP disclosed
US-5646169-A ADMINISTERING SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES TO HUMANS OR OTHER MAMMALS BEECHAM GROUP P.L.C. (GB) 1997-07-08 US disclosed
US-5521201-A SUBSTITUTED-THIAZOLIDINEDIONE DERIVATIVES BEECHAM GROUP P.L.C. 1996-05-28 US disclosed
US-5260445-A Hypoglycemic BEECHAM GROUP P.L.C. (GB) 1993-11-09 US disclosed
US-5232925-A Treating hypertension BEECHAM GROUP P.L.C. (GB) 1993-08-03 US disclosed
US-5194443-A Thiazolinediones, Hypoglycemic Agents, Antilipemic Agents BEECHAM GROUP P.L.C. (GB) 1993-03-16 US disclosed
US-5002953-A Substituted Thiazolidinedione Derivatives BEECHAM GROUP P.L.C. (GB) 1991-03-26 US disclosed
EP-0306228-A1 Substituted thiazolidinedione derivatives BEECHAM GROUP PLC (GB) 1989-03-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049240-A1 NOVEL COMPOUNDS GRK1, GRK3, GRK7 ALDH1A1 1255/4885HPGD 3027/4885HTT 450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.